A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease

Inclusion Criteria: * Age\>18 years and has a diagnosis of ESRD * On a three-times per week hemodialysis regimen * On a stable dose of a phosphate-binding agent for at least one month prior to study entry. * If on vitamin D supplementation or calcitriol, must be on a stable dose for at least one month prior to study entry. * Hct \>= 20% * Serum Ca level of 8 mg/dL to 10.5 mg/dL Exclusion Criteria: * Is pregnant or lactating * Clinically significant GI disorder * Has tertiary hyperparathyroidism or is immediately post-operative from a parathyroidectomy (within the first 3 months post-op or the plasma Ca is \<7 mg/dL) * ferritin\>800 ng/mL * Unstable medical condition unsuitable for the study in the opinion of investigator * Has been treated with an investigational agent within 30 days of enrollment * Has a history of documented iron allergy or hemochromatosis